Literature DB >> 30259639

Embryonic exposure to 4-methylimidazole leads to zebrafish myofibril misalignment.

Jen-Ning Tsai1,2, Chiao-Yin Sun3, Yu-Ju Ding4, Yun-Hsin Wang4, Kang-Chieh Lo4, Chi-Chung Wen5, Jia-Wei Lin6, Chiung-Fang Chang7, Li-Sung Hsu2,8, Hui-Min Chen9, Tsorng-Harn Fong9, Yau-Hung Chen4.   

Abstract

4-methylimidazole (4-MI) is an imidazole-derived organic chemical compound that can be used as a raw material in the manufacture of diverse chemicals and has been identified as an ingredient of caramel color in soybean sauce, beers, and other soft drinks. The aim of the present study was to investigate the teratogenic effects of 4-MI during zebrafish embryogenesis. Zebrafish embryos were treated with different dosages of 4-MI (0-120 mM) for different exposure durations (12-60 hours). The percentages of embryos with malformed phenotypes increased as the exposure dosages and duration time of 4-MI increased. We also used immunofluorescence and transmission microscopy to evaluate the subtle changes in the myofibril alignment and ultrastructure of muscle organization. Our data showed that 4-MI treatment disturbs muscle fiber alignment. Electron microscopy data indicated that Z-lines were undetectable in the 4-MI-treated embryos. Although the thick and thin filaments were visible, they were all disorganized. In addition, zebrafish embryos treated by 4-MI exhibited aberrant expression of 2 muscle-specific genes, myod and myogenin. Taken together, we concluded that early exposure to 4-MI affects zebrafish myogenesis, especially in myofibril alignment.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  4-methylimidazole; myogenesis; zebrafish

Mesh:

Substances:

Year:  2018        PMID: 30259639     DOI: 10.1002/tox.22640

Source DB:  PubMed          Journal:  Environ Toxicol        ISSN: 1520-4081            Impact factor:   4.119


  1 in total

1.  Quantification of 4-Methylimidazol in NMRI Mice Plasma and Cerebrospinal Fluid (CSF) by Using Liquid Chromatography Tandem Mass Spectrometry.

Authors:  Fereshteh Mehri; Firouzeh Nazari; Zohreh Fasihi; Farzad Kobarfard
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.